Welcome to our dedicated page for Avadel Pharmaceu news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceu stock.
Avadel Pharmaceuticals plc was a commercial-stage biopharmaceutical company focused on sleep medicine before its acquisition by Alkermes plc. Its company updates centered on LUMRYZ, an FDA-approved sodium oxybate extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
Recurring developments included LUMRYZ commercialization, clinical and regulatory disclosures for the REVITALYZ trial in idiopathic hypersomnia, operating and financial results, material agreements, shareholder voting matters, governance items and capital-structure changes tied to its public-company status and completed acquisition.
Avadel Pharmaceuticals (NASDAQ:AVDL) filed an Opening Position Disclosure under Rule 8.1(a)&(b) of the Irish Takeover Panel Rules dated 5 November 2025 covering the position at 4 November 2025.
The company is listed as the offeree. It reported no owned or short positions in any class of its relevant securities held by the discloser. Directors collectively held 794,959 ordinary shares (0.81%) and 4,347,557 underlying stock awards/options as of midnight 4 November 2025. Folio Investments reported 20 shares (0.00%).
No indemnities or voting arrangements were disclosed, no Supplemental Form 8 was attached, and the disclosure contact is Jerad Seurer.
Avadel Pharmaceuticals (Nasdaq: AVDL) reported third quarter 2025 results and a corporate update on Nov 4, 2025. Key financial and corporate items:
- LUMRYZ net product revenue $77.5M in Q3 2025, up 55% year-over-year.
- Approximately 3,400 patients on LUMRYZ as of Sep 30, 2025, up 48% year-over-year.
- Gross profit $81.6M (105% of revenue), reflecting a $9.5M royalty reversal tied to the Jazz settlement.
- Net income $20,000 (EPS $0.00) and cash, cash equivalents and marketable securities of $91.6M at Sep 30, 2025.
Corporate developments: Avadel entered a definitive agreement to be acquired by Alkermes for up to $20.00 per share (≈$2.1B), expected to close in Q1 2026 subject to shareholder, regulatory and Irish High Court approvals. Avadel also announced a global settlement with Jazz dismissing litigation and obtained expanded commercialization timing and royalty terms. Avadel licensed valiloxybate from XWPharma and paid a $15M upfront in Q3 with an additional $5M due in Q4 2025.
Alkermes (Nasdaq: ALKS) agreed to acquire Avadel (Nasdaq: AVDL) for $18.50 per share in cash plus a non-transferable CVR of $1.50 per share contingent on FDA approval for idiopathic hypersomnia, valuing the deal at up to $20.00 per share and ≈$2.1 billion. The boards approved the transaction, which is expected to close in Q1 2026 subject to regulatory and shareholder approvals.
The acquisition adds FDA-approved LUMRYZ (once-at-bedtime sodium oxybate) with expected 2025 net revenues of $265–$275 million, ~3,100 patients on therapy as of June 30, 2025, and a U.S. oxybate-eligible population >50,000. Alkermes expects the deal to be immediately accretive and will finance with cash on hand plus new debt, with J.P. Morgan providing committed financing.
Avadel Pharmaceuticals (NASDAQ:AVDL) announced a global settlement with Jazz Pharmaceuticals resolving all litigation and mutually dismissing lawsuits with prejudice.
Key terms include a $90 million payment from Jazz to Avadel, Jazz's waiver of royalties/damages on LUMRYZ sales through September 30, 2025, and a perpetual worldwide license from Jazz covering patents that could be asserted against LUMRYZ for all indications. Avadel will pay Jazz ongoing royalties of 3.85% of net narcolepsy sales (possible reduction to 3.75%) starting October 1, 2025, and 10% royalties (possible reduction to 9.5%) on LUMRYZ for any future FDA-approved indications beginning no earlier than March 1, 2028, both through February 18, 2036.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced on October 13, 2025 that its Compensation Committee approved inducement option awards for seven new employees totaling 161,600 ordinary shares under the company's 2021 Inducement Plan.
The non-statutory options carry a 10-year term and vest over four years with 25% vesting after one year and 25% on each of the second, third, and fourth anniversaries of each employee's start date. Awards are granted as inducements under Nasdaq Listing Rule 5635(c)(4) and are subject to the 2021 Inducement Plan and individual award agreements.
Avadel Pharmaceuticals (NASDAQ:AVDL) is celebrating a five-year milestone in supporting sleep research through its partnership with the American Academy of Sleep Medicine Foundation (AASM Foundation). As the inaugural corporate sponsor of the Young Investigator Research Forum (YIRF) since 2021, Avadel has helped empower numerous trainees and junior faculty in sleep science.
The company served as the lead sponsor for the AASM Fellow Boot Camp in June 2025, designed for incoming Sleep Medicine Fellowship residents. Since 2022, the collaboration has resulted in $1.7 million in grants awarded across five projects focusing on central disorders of hypersomnolence, through partnerships with Wake Up Narcolepsy and the Hypersomnia Foundation.
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced the approval of inducement awards for five new employees. The Compensation Committee of Avadel's Board of Directors granted non-statutory options to purchase 165,520 ordinary shares under the company's 2021 Inducement Plan.
The options come with a ten-year term and feature a four-year vesting schedule, with 25% vesting annually starting from each employee's first anniversary. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment acceptance.
Avadel Pharmaceuticals (Nasdaq: AVDL) will present new data on LUMRYZ™, its once-nightly sodium oxybate treatment for narcolepsy, at World Sleep 2025 in Singapore. The company will showcase 17 abstracts, including one oral presentation and 16 posters.
Key highlights from the REFRESH real-world study (n=51) demonstrated clinically meaningful improvements in patients switching from twice-nightly oxybates and those new to treatment. After 4 months, 70-90% of participants showed improvement across different patient groups. The study revealed improvements in excessive daytime sleepiness, narcolepsy symptoms, quality of life, and reduced need for stimulants.
LUMRYZ, approved by FDA in May 2023 for adults and October 2024 for pediatric patients (7+ years), is the first and only once-at-bedtime treatment for narcolepsy, offering advantages over twice-nightly alternatives.
Avadel Pharmaceuticals (Nasdaq: AVDL) has secured an exclusive global license agreement with XWPharma for valiloxybate, a GABAB receptor agonist designed for sleep disorders. The deal includes a $20 million upfront payment plus potential milestone payments and royalties.
Valiloxybate is notable as the only once-at-bedtime, salt-free and artificial sweetener-free extended-release oxybate treatment for narcolepsy and idiopathic hypersomnia (IH). The company plans to initiate a pharmacokinetic study in Q4 2025, followed by a pivotal PK trial in H2 2026.
This strategic acquisition builds upon Avadel's existing sleep medicine portfolio and success with LUMRYZ, strengthening their position in sleep disorder treatments.
Avadel Pharmaceuticals (Nasdaq: AVDL), a biopharmaceutical company, has announced its participation in three major upcoming investor conferences in September 2025. The company will participate in fireside chat sessions at the 2025 Wells Fargo Healthcare Conference on September 5, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10.
All presentations will be available via webcast on the company's investor relations website for 90 days following each conference.